This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Miocamycin
DrugBank Accession Number
DB13287
Background

Miocamycin is a macrolide type antimicrobial 1. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia 2. It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment 1.

Type
Biotech
Groups
Approved
Synonyms
  • Midecamycin acetate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Miocamycin.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Miocamycin.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Miocamycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Miocamycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Miocamycin.
AlectinibThe metabolism of Alectinib can be decreased when combined with Miocamycin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Miocamycin.
AlpelisibThe metabolism of Alpelisib can be decreased when combined with Miocamycin.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Miocamycin.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Miocamycin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
J01FA11 — Miocamycin
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
3T48CPS7U2
CAS number
55881-07-7

References

General References
  1. Holliday SM, Faulds D: Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. [Article]
  2. Kegg Japanese Pharmacopoeia [Link]
  3. AIFA Product Information: Macroral (miocamycin) for oral use [Link]
ChemSpider
16735908
RxNav
236200
ChEMBL
CHEMBL1091024
ZINC
ZINC000169677000
Wikipedia
Miocamycin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Granule, for suspensionOral250 MG/5ML
Granule, for suspensionOral300 MG
Granule, for suspensionOral600 MG
Granule, for suspensionOral900 MG
Tablet, coatedOral300 MG
Tablet, coatedOral600 MG
TabletOral300 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at June 23, 2017 20:39 / Updated at October 27, 2020 21:12